At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,239 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Global Multi-centre Observational Study in RA Patients Who Are Non Responders or Intolerant to a Single TNF Inhibitor.
In Brief
An observational study for Rheumatoid Arthritis. Completed, enrolled 1,239 participants across 215 sites in 12 countries.
Detailed Summary
This multicenter, prospective, observational study will assess the efficacy of MabThera/Rituxan (rituximab) and alternative TNF-inhibitors in patients with rheumatoid arthritis who are non-responders or intolerant to a single previous TNF-inhibitor. Data will be collected from each patient from the time of change in biologic therapy for 12 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesCanada, Colombia, France, Germany, Greece, Italy, Mexico, Monaco, Norway, Portugal, Spain, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
Primary CompletionMar 2012
First PostedMar 2012
TodayJul 2026
First PostedMar 19, 2012
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.3 years ago